---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-182569"
form_type: "8-K"
ticker: "ACH"
cik: "0000075252"
company_name: "ACCENDRA HEALTH INC/VA/"
filed_at: "2024-07-23T23:59:59+00:00"
generated_at: "2026-05-31T18:19:19.433733+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Owens & Minor to buy Rotech for $1.36B cash; expects ~$0.15 EPS accretion in second year

## Summary
- Purchase price $1.36B cash; net $1.32B after ~$40M tax benefits; ~6.3x LTM EBITDA ex-synergies.
- Rotech 2023 revenue ~$750M with ~30% EBITDA margin; 4,200+ employees, ~325 locations in 46 states.
- Expected close by end of 2024; subject to HSR; financed with $775M term loan B and $625M bridge.
- Synergies ~$50M by end of year three; adjusted EPS neutral in first full year, accretive in second year.
- Owens & Minor reaffirms 2024 full-year guidance; preliminary Q2 results reported separately.

## SEC filing metadata
- accession: 0001193125-24-182569
- form_type: 8-K
- ticker: ACH
- cik: 0000075252
- company_name: ACCENDRA HEALTH INC/VA/
- filed_at: 2024-07-23T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/75252/000119312524182569/0001193125-24-182569-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/75252/000119312524182569/d861390d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-182569
- JSON: https://secwatch.observer/filing/0001193125-24-182569.json
- Plain text: https://secwatch.observer/filing/0001193125-24-182569.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.